Patients with chronic lymphocytic leukemia (CLL) who relapse or stop responding to standard treatment face tough odds. At the Community Case Forum in Princeton, New Jersey, on September 28, 2026, clinicians got right to the point. They debated how to bring the best new therapies to these patients and how to keep care teams working in sync.
CAR T cell therapy is no longer just a future hope. It is now a real option in these talks. This treatment uses a patient’s own T cells, reprogrammed to hunt leukemia. For people who have run out of standard choices, it can change everything. Swetha Hinton, APRN-CNP, described ongoing clinical trials at The Ohio State University. She said these studies give patients a real shot at lasting responses when little else works. The forum showed that targeted drugs and cell therapies are not just ideas. They are now part of the toolkit for hard-to-treat CLL.
In October 2026, the FDA expanded approval of pirtobrutinib (Jaypirca) for adults with previously untreated CLL/SLL without known 17p deletion, marking a major update in frontline CLL therapy.
Advanced practice providers anchor CLL care
But science is only half the battle. Moderators Emily Tomasulo, DO, FACP, and Hinton made it clear: advanced practice providers (APPs) and oncology nurses are essential. Tomasulo called APPs the backbone of CLL care. Hinton listed nurse practitioner duties—seeing new patients, managing treatments, leading trial talks, and making sure protocols are followed. In research, nurse practitioners act as co-investigators. They guide patients through trial steps and work closely with doctors to keep standards high.
For clinicians who do not see CLL often, these forums are more than lectures. They are lifelines. Tomasulo said that talking through real cases and networking with peers gives practical tips that help right away. These meetings matter for anyone who must turn new data into real decisions. CAR T cell therapy is moving from trial to clinic. Teams need to be ready.
The Association of Community Cancer Centers (ACCC) has emphasized the need for patient-centered approaches in relapsed/refractory CLL, particularly after covalent BTK inhibitor therapy, and highlights the importance of multidisciplinary coordination for CAR T-cell therapy in community settings.
Bridging evidence and practice in community oncology
Community Case Forums connect academic breakthroughs with everyday oncology practice. These meetings bring together teams to review real cases and new data. The goal is simple. Make sure advances like CAR T cell therapy reach patients everywhere, not just in big centers. This model matches what happened in earlier reported cases, where access to advanced care depended on teamwork across hospitals and specialties.
CLL treatment is getting more complex. The forum’s message was blunt. Success depends on both new science and strong teams. Advanced practice providers now play a role at every step. That is not optional. It is required. Oncology teams who want the best results must keep up with both innovation and teamwork. No shortcuts.
CAR T cell therapy is not the only change. New targeted drugs are coming fast. An October 2026 MedPage Today report confirmed the FDA’s expanded approval of pirtobrutinib (Jaypirca) for adults with previously untreated CLL/SLL without known 17p deletion. This is a big step. Lilly says pirtobrutinib is now in four phase 3 trials for CLL/SLL, including BRUIN CLL-321 and BRUIN CLL-322. The clinical program is active and growing.
The CLL Society keeps publishing new reviews on drug classes. These include approved monoclonal antibodies, CAR-T, and experimental bispecific antibodies. The standard of care for relapsed or refractory CLL is shifting. More complex drug combinations are now the norm.
